title: Measles revaccination response in a school-age population.
abstract: Due to the dramatic upsurge in the incidence of measles, the American Academy of Pediatrics and the Immunization Practices Advisory Committee of the Centers for Disease Control revised their measles immunization policies in 1989 to include a routine two-dose schedule. The objectives of this study were the following: (1) determine the prevalence of immunologically measles-susceptible subjects in a previously vaccinated, school-age, military dependent population; and (2) assess risk factors to identify immunologically measles-susceptible subjects. Serum was collected just prior to measles revaccination and again 2 weeks later. Measles-specific IgG and IgM titers were determined by enzyme-linked immunosorbent assay. Immunologically measles-susceptible subjects constituted 9.8% of the population. The interval since previous measles vaccination was significantly related to pre- and postrevaccination IgG titers in a repeated-measures analysis of variance model. The magnitude of increase in IgG titer following revaccination and analysis of trend for proportions of measles-susceptible subjects were significantly related to the age of initial vaccination. This study supports continued measles revaccination; in addition, revaccination appears to be of greater value at 11 to 12 years of age than at 4 to 6 years of age.
authors.affiliation: Department of Pediatrics, William Beaumont Army Medical Center, El Paso, Texas 79920.
authors.forename: R R
authors.initials: RR
authors.lastname: Wittler
authors.forename: B C
authors.initials: BC
authors.lastname: Veit
authors.forename: S
authors.initials: S
authors.lastname: McIntyre
authors.forename: M
authors.initials: M
authors.lastname: Schydlower
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004198:Disease Susceptibility; D004338:Drug Combinations; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008457:Measles / Q000517:prevention & control*; D008458:Measles Vaccine / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000276:immunology; D012411:Rubella Vaccine / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D004338:Drug Combinations; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine